Biocartis wins prestigious Galenus Prize with its Idylla(TM) NRAS-BRAF Mutation Test for colorectal cancer


Yesterday evening, Biocartis won the prestigious 2016 Galenus Prize for the Most Innovative Medical Device, leading the way to better treatments, with its fully automated Idylla(TM) NRAS-BRAF Mutation Test (CE-IVD) for colorectal cancer patients.  

The Galenus Prize is a prestigious international award that exists for over 30 years. Every year, it is organized in Belgium and Luxembourg by Roularta HealthCare, publisher of 'Artsenkrant/Le journal du Médecin'. An expert jury awards three initiatives:

  - The Pharmacology Award: recognition for a work on clinical and/or fundamental pharmacology by a researcher or a group of researchers

  - The Treatment Award: recognition for the most innovative treatment

  - The Medical Device Award: only existing since two years, this category awards medical devices that can lead to a better treatment

Caroline Collard, Head of Marketing of Biocartis, commented "The Jury was mainly impressed that the Idylla(TM) NRAS-BRAF Mutation Test analyzes results in approx. two hours, allowing the clinician to start up the right treatment in only 1 or 2 days, whereas traditional testing methods today can take up to several weeks. This is not an ideal situation, neither for the clinician who is treating the patient, nor for the patient him/herself. We are very proud with this great award, which helps support the power of rapid, high precision diagnostics that only have one ultimate goal: to make high precision medicine accessible for every patient."

Pfizer won in the category 'Treatment' with its breast cancer treatment Ibrance. 



Interested in a regular update of the Life Sciences and biotech sector in Flanders?